Seeking future for domestic pharmaceutical equipment: technology and product manufacturing quality need to be improved

As a rigid need, medicine is constantly developing and progressing in the process of fighting human diseases
.
As the upstream of medicine, the pharmaceutical equipment industry plays an important role, and its design and R&D level directly affects the quality of medicines
.
At present, after years of development, China's pharmaceutical equipment industry has basically formed a complete, complete and independent industrial system.
Both technical standards and overall strength have been significantly improved, and the industrial scale has continued to expand
.
So, what is the current pattern of the pharmaceutical equipment industry? Chutian Technology mentioned in the Investor Relations Activity Record Form released on November 24 that from a global background, two types of companies have emerged in Europe and America.
One type is represented by Thermo Fisher Scientific, Danaher, and Sartorius.
The company is mainly engaged in biological front-end process equipment, raw and auxiliary materials, and the other is the main equipment company represented by Xingdeke (formerly Bosch), Ima, Gollinger, Maximilian and Ullmann
.
In China, represented by Chutian and Tofflon, they already have these two businesses at the same time or are planning to cultivate these two businesses.
From the perspective of the richness of the product chain, Chinese companies already have advantages in the world
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) The domestic pharmaceutical equipment industry is ushering in a new round of opportunities.
The domestic pharmaceutical equipment industry is ushering in a new round of opportunities
.
On the one hand, biological drugs and innovative drugs are developing rapidly.
With the continuous development of pharmaceutical biotechnology, the entire biopharmaceutical market is in the ascendant, and the upstream pharmaceutical equipment market will also have a very broad development space in the future
.
On the other hand, policies also encourage the development of high-end pharmaceutical equipment, and the pace of domestic substitution of imports is accelerating
.
Some organizations pointed out that the pharmaceutical equipment market has entered a growth period of overall stability and partial breakthroughs: with the upstream pharmaceutical industry picking up, China's pharmaceutical equipment market is expected to reach US$4.
58 billion in 2025, with a compound growth rate of 8.
1%
.
In the face of new opportunities, local pharmaceutical machinery companies including Chutian Technology and Tofflon are stepping up their deployment.
For example, Chutian has established holding companies Chutian Siyoute and Chutian Microsphere to accelerate their development in the field of biopharmaceuticals.
Layout; Tofflon expanded the production capacity of biological equipment through investment to further enhance the company’s overall solution capabilities for biological engineering
.
However, as a whole, there is still a certain gap between domestic pharmaceutical equipment and international equipment
.
In this research activity, Chutian Technology also expressed that the company's aseptic packaging products and post-packaged products are already comparable to the international level, but there is still a certain gap in other products
.
For example, in the field of biological front-end, due to the late start of domestic enterprises and weak technology, there are still shortcomings in technology and quality
.
Technology and product manufacturing quality needs to be improved.
As a domestic pharmaceutical equipment giant, Chutian Technology's point of view is that the gap between domestic equipment and international equipment is mainly reflected in technology precipitation and product manufacturing quality
.
In this regard, the company also stated that it will continue to vigorously promote manufacturing innovation, quality improvement, and product technology research and development innovation
.
However, technology and product quality cannot be improved overnight.
It requires continuous R&D investment, long-term experience accumulation, and persevering craftsmanship
.
In recent years, it can also be seen that domestic pharmaceutical companies are starting to increase R&D investment and focus on personnel training, closely following the development trend of the biomedical industry and the application of new technologies, and continuously improve technological innovation capabilities and high-quality R&D.
Products promote the development of the industry
.
Research and development is an important part
.
Under the Great Health China strategy, the pharmaceutical industry is facing more and more stringent regulations, and the requirements for drug safety and effectiveness are constantly improving.
In this context, pharmaceutical equipment also needs to keep pace with the times and meet the process requirements of pharmaceutical factories
.
From the perspective of R&D investment, domestic pharmaceutical equipment companies are increasingly working on R&D
.
For example, in 2018, 2019, and 2020, Chutian Technology invested 240 million yuan, 230 million yuan and 290 million yuan in R&D respectively, and the proportion of R&D investment in operating revenue was 9.
09%, 7.
43% and 8.
05%, respectively
.
In the first nine months of 2021, Chutian Technology’s R&D expenses will be 307 million yuan, an increase of 60.
7% year-on-year; Tofflon’s R&D investment in 2018, 2019, and 2020 will be 98 million yuan, 119 million yuan, and 156 million yuan, respectively.
, Respectively accounting for 5.
10%, 5.
26%, and 5.
77% of the current revenue
.
In the first three quarters of this year, Tofflon’s research and development expenses were 166 million yuan, an increase of 74.
81% over the same period last year
.
It can be seen from the data that in recent years, the overall R&D investment of these domestic pharmaceutical machine companies has shown an increasing trend year by year, and the proportion of revenue in that year has also been increasing
.
Talent is the source and driving force of enterprise development, and has a close relationship with research and development
.
In the pharmaceutical equipment industry, continuous R&D cannot be separated from the support of talents, especially those high-quality professionals who have rich experience and understand both pharmaceutical technology and equipment
.
With the rapid development of the pharmaceutical equipment industry, the "grabbing war" between pharmaceutical machinery companies is also staged.
Companies including Chutian and Dongfulong have all moved to attract Wutong Phoenix
.